

# Hydroxychloroquine in Mild Graves' Orbitopathy

NCT05126147

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	National Taiwan University Hospital
<b>Enrollment</b>	108 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Mild GO according European Group on Graves' orbitopathy (EUGOGO) guidelines diagnosed by endocrinologist and ophthalmologist.
- No previous treatment of GO except for eyedrops
- Euthyroidism (normalized free T4 and TSH) for at least 2 months. If radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months.

### Exclusion (16)

- Moderate-to-sever or sight-threatening GO according to EUGOGO guidelines diagnosed by endocrinologist and ophthalmologist.
- Pregnancy
- Drug or alcohol abuse
- Unable to comply with the study protocol
- Unable to obtain informed consent
- ... and 11 more (see full listing online)

## Locations (2 total)

---

National Taiwan University Hospital, Hsin-Chu branch, Hsinchu, Taiwan  
National Taiwan University Hospital, Taipei, Taiwan